Selective mitochondrial citrate transporter (SLC25A1) inhibitor
CTPI 2 is a selective mitochondrial citrate transporter (SLC25A1) inhibitor with a KD of 3.5 μM. CTPI 2 inhibits the proliferation of H1299 cells in a SLC25A1-dependent manner. It also re-sensitizes T1, T2, and T4 cells to Cisplatin (Cat. No. 2251). CTPI 2 inhibits tumor growth in
in vivo
models of non-small cell lung cancer (NSCLC). In high-fat diet fed mice CTPI 2 regulates glycolysis, prevents steatohepatitis and normalizes glucose tolerance and insulin sensitivity. CTPI 2 influences the inflammatory pathway by inhibiting IL-6 and TNFα production and M1 macrophage polarization.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-160834 |
| Réf. fabricant | 30000417 |
| Nom chimique ou matériau | 2-[[(4-Chloro-3-nitrophenyl)sulfonyl]amino]benzoic acid |
| CAS | 68003-38-3 |
| Quantité | 50 mg |
| Cible | Other Ion Pump/Transporter Inhibitors |
| Formule moléculaire | C<sub>13</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>6</sub>S |
| Pureté | 98% |
